Cargando…
Neurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder
BACKGROUND: This randomized, placebo-controlled, crossover trial examined the antidepressant efficacy of the muscarinic antagonist scopolamine in major depressive disorder subjects with more severe and refractory forms of major depressive disorder relative to previous reports. METHODS: Participants...
Autores principales: | Park, Lawrence, Furey, Maura, Nugent, Allison C, Farmer, Cristan, Ellis, Jessica, Szczepanik, Joanna, Lener, Marc S, Zarate, Carlos A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313153/ https://www.ncbi.nlm.nih.gov/pubmed/30184133 http://dx.doi.org/10.1093/ijnp/pyy051 |
Ejemplares similares
-
Pretreatment Differences in BOLD Response to Emotional Faces Correlate with Antidepressant Response to Scopolamine
por: Furey, Maura L., et al.
Publicado: (2015) -
Ketamine normalizes brain activity during emotionally valenced attentional processing in depression
por: Reed, Jessica L., et al.
Publicado: (2018) -
Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine
por: Wohleb, Eric S., et al.
Publicado: (2017) -
Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression
por: Guo, Wei, et al.
Publicado: (2018) -
Correction: Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression
por: Guo, Wei, et al.
Publicado: (2019)